COMPANY
Lungpacer Medical
Funding and NIH signals
- SEC Form D raise Raised $7.83M in debt securities (Form D filed Oct 14, 2026); +1 other Form D filing in the last 12 months. SEC Form D 0001708893-26-000005 (Oct 14, 2026)
Evidence (2 events)
- Oct 14, 2026 · SEC Form D 0001708893-26-000005
Name of Issuer: Lungpacer Medical, Inc.; CIK: 1708893; Address: Exton, PA; Submission type: D; Filing date: 2026-10-14; Industry Group: Other Health Care; Date of First Sale: 2026-09-30; Types of Securities Offered: Debt, Other (Unsecured Convertible Promissory Notes); Business combination transaction: false; Total Offering Amount: 30000000; Total Amount Sold: 7833333; Federal exemptions: 06b - Apr 28, 2026 · SEC Form D 0001708893-26-000002
Name of Issuer: Lungpacer Medical, Inc.; CIK: 1708893; Address: Exton, PA; Submission type: D; Filing date: 2026-04-28; Industry Group: Other Health Care; Date of First Sale: 2026-04-23; Types of Securities Offered: Debt, Other (Unsecured Convertible Promissory Notes); Business combination transaction: false; Total Offering Amount: 20000000; Total Amount Sold: 12000000; Federal exemptions: 06b || Name of Issuer: Lungpacer Medical, Inc.; CIK: 1708893; Address: Exton, PA; Submission type: D/A; Filing date: 2026-07-02; Industry Group: Other Health Care; Date of First Sale: 2026-04-23; Types of Securities Offered: Debt, Other (Unsecured Convertible Promissory Notes); Business combination transaction: false; Total Offering Amount: 20000000; Total Amount Sold: 16000000; Federal exemptions: 06b || Name of Issuer: Lungpacer Medical, Inc.; CIK: 1708893; Address: Exton, PA; Submission type: D/A; Filing date: 2026-10-08; Industry Group: Other Health Care; Date of First Sale: 2026-04-23; Types of Securities Offered: Debt, Other (Unsecured Convertible Promissory Notes); Business combination transaction: false; Total Offering Amount: 20000000; Total Amount Sold: 12000000; Federal exemptions: 06b
- Oct 14, 2026 · SEC Form D 0001708893-26-000005
Timeline
- Trial start Not phased (device or behavioral study): A Post-Approval Multicenter Study to Assess the Continued Safety and Effectiveness of the AeroPace® System source ↗
- Trial start Not phased (device or behavioral study): STimulation to Activate RespIration source ↗
- FDA FDA PMA approval: AeroPace® System — P240012, Dec 4, 2024. Applicant at approval: Lungpacer Medical USA, Inc. source ↗
- Trial start Not phased (device or behavioral study): Phrenic Nerve Stimulation-Induced Lung ReAeration Trial source ↗
- Trial start Not phased (device or behavioral study): A Protocol Comparing Temporary Transvenous Diaphragm Pacing to Standard of Care for Weaning From Mechanical Ventilation source ↗
- Trial start Not phased (device or behavioral study): Percutaneous Temporary Placement of a Transvenous Phrenic Nerve Stimulator for Diaphragm Pacing Using Jugular Access source ↗
- Trial start Not phased (device or behavioral study): Percutaneous Temporary Placement of a Phrenic Nerve Stimulator for Diaphragm Pacing source ↗
- Trial start Not phased (device or behavioral study): Percutaneous Temporary Placement of a Phrenic Nerve Stimulator for Diaphragm Pacing (RESCUE1) source ↗
- Trial start Not phased (device or behavioral study): Percutaneous Temporary Placement of a Phrenic Nerve Stimulator for Diaphragm Pacing, a First in Human Trial source ↗
Upcoming milestones
- Aug 31, 2028 (ESTIMATED) · Not phased · A Post-Approval Multicenter Study to Assess the Continued Safety and Effectiveness of the AeroPace® System · NCT07477054
Clinical trials (lead sponsor) 8
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07477054 | A Post-Approval Multicenter Study to Assess the Continued Safety and Effectiveness of the AeroPace® System | Not phased (device or behavioral study) | Not yet recruiting | Oct 31, 2026 | Aug 31, 2028 (estimated) |
| NCT06832306 | STimulation to Activate RespIration | Not phased (device or behavioral study) | Recruiting | May 28, 2025 | Sep 30, 2026 (estimated) |
| NCT03783884 | A Protocol Comparing Temporary Transvenous Diaphragm Pacing to Standard of Care for Weaning From Mechanical Ventilation | Not phased (device or behavioral study) | Terminated | Jun 14, 2019 | Dec 28, 2022 (actual) |
| NCT04844892 | Phrenic Nerve Stimulation-Induced Lung ReAeration Trial | Not phased (device or behavioral study) | Completed | Aug 25, 2021 | Feb 1, 2023 (actual) |
| NCT03096639 | Percutaneous Temporary Placement of a Phrenic Nerve Stimulator for Diaphragm Pacing | Not phased (device or behavioral study) | Completed | Sep 14, 2017 | Dec 29, 2019 (actual) |
| NCT03107949 | Percutaneous Temporary Placement of a Phrenic Nerve Stimulator for Diaphragm Pacing (RESCUE1) | Not phased (device or behavioral study) | Completed | Jun 20, 2017 | Jan 30, 2018 (actual) |
| NCT03659552 | Percutaneous Temporary Placement of a Transvenous Phrenic Nerve Stimulator for Diaphragm Pacing Using Jugular Access | Not phased (device or behavioral study) | Completed | May 7, 2018 | Jun 30, 2018 (actual) |
| NCT02670460 | Percutaneous Temporary Placement of a Phrenic Nerve Stimulator for Diaphragm Pacing, a First in Human Trial | Not phased (device or behavioral study) | Completed | 2015-10 | 2016-04 (actual) |
FDA records (last 2 years)
- FDA PMA approval: AeroPace® System — P240012, Dec 4, 2024. Applicant at approval: Lungpacer Medical USA, Inc. source ↗
Connect
See your connections at Lungpacer Medical on LinkedIn (search by name, results not checked)